BioSpace News Archive

Bristol Myers Squibb (NYSE: BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of CAMZYOS® (mavacamten) for the treatment of symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy (HCM) in adult patients.

Apotex Corp. has expanded its oncology product portfolio with the launch of Bendamustine hydrochloride injection in the United States.

AdvaMed, the MedTech Association, released the findings of a new national poll on radiation therapy and cancer treatment revealing broad support for greater federal investment in the proven cancer treatment of radiation therapy, to bring down costs and expand access for patients.

Blue Water Biotech, Inc., a biotechnology company spanning multiple sectors, announced the appointment of Jay Newmark, M.D., MBA as the Company’s Chief Medical Officer.

Corcept Therapeutics Incorporated announced it will report first quarter financial results and provide a corporate update on May 3, 2023.

Sight Sciences, Inc. announced plans to present at the upcoming Bank of America Securities 2023 Health Care Conference in Las Vegas, NV.

NexImmune, Inc. (Nasdaq: NEXI) today announced that clinical data from its Phase 1/2 dose escalation study of NEXI-001 will be presented in a poster session at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting in Chicago, June 2 – June 6, 2023.

SELLAS Life Sciences Group, Inc. announced acceptance of an abstract for a poster presentation at the American Society of Clinical Oncology Annual Meeting, taking place June 2-6, 2023 in Chicago and virtually.

BioMarin Pharmaceutical Inc. announced financial results for the first quarter ended March 31, 2023.

Precigen, Inc. announced clinical data from the Phase 1 dose escalation study of PRGN-3005 UltraCAR-T in patients with advanced, recurrent platinum resistant ovarian cancer, and the Phase I study of PRGN-2009 AdenoVerse immunotherapy alone or in combination with an anti-PDL1/TGF-Beta trap checkpoint inhibitor in patients with HPV-associated cancers will be presented at the 2023 ASCO Annual Meeting taking place from June 2-6, 2023 at McCormick Place in Chicago, Illinois.